Komoriya K, Nagata I, Takeshita T, Yamamoto I
Pharmacological Research Department, Teijin Institute for Bio-medical Research II, Tokyo, Japan.
J Pharmacobiodyn. 1991 Aug;14(8):443-7. doi: 10.1248/bpb1978.14.443.
TI-31, at concentrations of 10 and 100 microM, suppressed the antibody response to T cell-dependent (sheep red blood cells, SRBC) and -independent antigens (trinitrophenyl-lipopolysaccharide, TNP-LPS and TNP-Ficoll). The anti-SRBC response was suppressed by TI-31 when T cells were replaced by a supernatant of concanavalin A (Con A)-stimulated spleen cells, indicating the drug had influence on T lymphocytes, B lymphocytes and macrophages. TI-31 augmented the Con A-induced suppressor T cell (Ts) assessed by anti-SRBC plaque-forming cells response in vitro. The drug (10 mg/kg, p.o.) potentiated antigen specific Ts induction in vitro after injection of a high dose of SRBC. The results demonstrate that TI-31 enhanced Ts induction, which resulted in a diminution of antibody formation.
浓度为10微摩尔和100微摩尔的TI-31抑制了对T细胞依赖性(绵羊红细胞,SRBC)和非依赖性抗原(三硝基苯基-脂多糖,TNP-LPS和TNP-菲可)的抗体反应。当用伴刀豆球蛋白A(Con A)刺激的脾细胞上清液替代T细胞时,TI-31抑制了抗SRBC反应,表明该药物对T淋巴细胞、B淋巴细胞和巨噬细胞有影响。TI-31增强了通过体外抗SRBC空斑形成细胞反应评估的Con A诱导的抑制性T细胞(Ts)。该药物(10毫克/千克,口服)在注射高剂量SRBC后增强了体外抗原特异性Ts诱导。结果表明,TI-31增强了Ts诱导,从而导致抗体形成减少。